Since anti-CD20 treatment can partially modulate anti-FVIII immune responses in hemophilia A mice, we investigated whether a combination therapy using anti-CD20 to deplete B-cells and IL-2/IL-2mAb complexes to expand Treg cells (24) can more consistently reduce anti-FVIII responses. The gene discussed is IL2; the disease is hemophilia A.